Prior to launching any new product on the market, it’s important to evaluate its safety, especially for those products that will come into direct contact with the skin. The Human Repeat Insult Patch Test (HRIPT or RIPT test) is considered the gold standard for in vivo safety assessment, ensuring that tested products do not cause skin irritation or induce skin sensitivity. Additionally, conducting an HRIPT study enables you to evaluate the potential allergenicity of your product and is a crucial safety study to support the hypoallergenic claim.
For those in the cosmetics or personal care product industry, conducting safety evaluations through clinical testing, such as HRIPT, becomes an essential aspect of both product development and regulatory compliance.
At Zurko Research, our commitment to our clients and their consumers is steadfast. Through a wide range of safety clinical studies, including HRIPT, we strive to identify any potential irritation or sensitization issues, thus minimizing the risk of adverse reactions for consumers and ensuring the success of our clients.
At Zurko Research our commitment to excellence is reflected in the meticulous approach we take in Human Repeat Insult Patch Test (HRIPT) studies. Our testing process consists of three different phases, ensuring a comprehensive evaluation of products that come into direct contact with the skin.
Dermatologist tested